ArticleMedical oncology (Northwood, London, England)2015
BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis.
Article in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.International journal of molecular sciences · 2025Article
- Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer.Scientific reports · 2024Article
- CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation.Aging · 2022Article
- Bioinformatic identification of differentially expressed genes associated with hepatocellular carcinoma prognosis.Medicine · 2022Article
- CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies.Journal of experimental & clinical cancer research : CR · 2022Review
- BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability.Signal transduction and targeted therapy · 2021Article
- Integrative Analysis of Gene Expression Through One-Class Logistic Regression Machine Learning Identifies Stemness Features in Multiple Myeloma.Frontiers in genetics · 2021Article
- BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.Cancer medicine · 2020Article
- Kinome expression profiling to target new therapeutic avenues in multiple myeloma.Haematologica · 2020Article
- Prognostic Prediction Using a Stemness Index-Related Signature in a Cohort of Gastric Cancer.Frontiers in molecular biosciences · 2020Article
- Aneuploidy: Cancer strength or vulnerability?International journal of cancer · 2019Review
- Transcriptome sequencing to detect the potential role of long non-coding RNAs in bovine mammary gland during the dry and lactation period.BMC genomics · 2018Article
- Review
- Review
- MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.Oncotarget · 2016Article
- Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is the second most common hematopoietic malignancy characterized by plasma cell proliferative disorder. In this study, we disclosed that expression of BUB1B significantly increased in high-risk myeloma patients especially in the most aggressive myeloma genetic subgroups of proliferation. Increased BUB1B expression promotes MM cell proliferation. Mechanism study showed that BUB1B expression was highly correlated to CDC20 and CCNB1/2 expression in MM cells, leading to increased MM cell proliferation. Therefore, BUB1B may be a potential target for MM treatment especially for high-risk MM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.